17 August 2017 - Newly-approved tablet formulation means improved patient convenience.

AstraZeneca and Merck today announced that the US FDA has granted approval for the PARP inhibitor, Lynparza (olaparib), as follows:

• New use of Lynparza as a maintenance treatment for recurrent, epithelial ovarian, fallopian tube or primary peritoneal adult cancer who are in response to platinum-based chemotherapy, regardless of BRCA status
  
• New use of Lynparza tablets (2 tablets twice daily) as opposed to capsules (8 capsules twice daily)
  
• Lynparza tablets also now indicated (conversion from the current accelerated approval) for the use in patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy
  

Read AstraZeneca press release